Publications from the Centre for Immuno-Oncology
Antigen-presenting mast cells are new players in breast cancer immunotherapy.
Luri-Rey C. et al, (2025), Nature medicine
Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer.
Ruiz-Fernández de Córdoba B. et al, (2025), Signal transduction and targeted therapy, 10
Immunocytokines and cytokine neutralization for cancer immunotherapy
Berraondo P. et al, (2025), Trends in Cancer
Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse
Heras-Murillo I. et al, (2025), Nature Communications, 16
Barriers to publishing early phase clinical trials: the oncologists' perspective.
Lucassen MJJ. et al, (2025), The oncologist, 30
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumors.
de Bono JS. et al, (2025), Clinical cancer research : an official journal of the American Association for Cancer Research
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models.
Garate-Soraluze E. et al, (2025), Journal for immunotherapy of cancer, 13
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Melero I. et al, (2025), Nature
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.
Ascierto PA. et al, (2025), Journal for immunotherapy of cancer, 13
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Lopez J. et al, (2025), Nature medicine
Cross-priming in cancer immunology and immunotherapy.
Luri-Rey C. et al, (2025), Nature reviews. Cancer
Phase 1 dose-escalation study of linclatamig, a LY6G6DxCD3 T cellengaging bispecific antibody, in patients with colorectal cancer Free
Fakih M. et al, (2025), CANCER RESEARCH, 85
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Melero I. et al, (2024), Nature
Regional and intratumoral adoptive T-cell therapy.
Olivera I. et al, (2024), Immuno-oncology technology, 24
Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines.
Berraondo P. et al, (2024), Cancer discovery, 14, 2021 - 2024
Targeting T-cell costimulation to the surface of tumor cells.
Eguren-Santamaría I. et al, (2024), Clinical cancer research : an official journal of the American Association for Cancer Research
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
Ascierto PA. et al, (2024), NEJM evidence, 3